Skip to content
Peptigraph home

Thymosin Alpha-1 Benefits: Claims vs What Studies Show

Benefits people claim for Thymosin Alpha-1, set against what published studies measured, and where no study exists.

Medical review pendingImmune modulatorUpdated
Strongest evidence
Human RCT
Human / animal studies
11 / 0
in our evidence file (PubMed search, 11 Oct 2026)
FDA status
Not approved
approved abroad

Claimed benefits and what studies show

Each row is an area where people claim a benefit, with the strongest study we summarise behind it. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

Thymosin Alpha-1 claimed benefits and the studies behind them
ClaimBest evidenceStudies (human / animal)What was measuredPage
Immune systemHuman RCT evidence, 4 of 45 / 028-day all-cause mortality; Safety and secondary outcomes; Infection rate and ICU stayEvidence for immune system
Liver healthHuman RCT evidence, 4 of 41 / 0Response rate; Low vs high dose; All-cause mortalityEvidence for liver health

Strongest study per claim: Immune system, BMJ 2025, PMID 39814420; Liver health, Internal medicine 2003, PMID 14606705.

What the studies measured

Thymosin Alpha-1 outcomes in published studies
OutcomeResultStudy typeSource
28-day all-cause mortality28-day mortality was 23.4% on thymosin alpha 1 and 24.1% on placebo (hazard ratio 0.99, P=0.93).Human RCTn = 1106BMJ 2025, PMID 39814420
Safety and secondary outcomesNo secondary or safety outcome differed significantly from placebo.Human RCTn = 1106BMJ 2025, PMID 39814420
Infection rate and ICU stayCulture-positive rates and ICU stay were lower with thymosin alpha 1.Human RCTn = 24Inflammation 2011, PMID 20549321
Response and survivalResponse was 57.1% vs 45.5%, not statistically different (P = 1.0).Human RCTn = 25Hepatology international 2009, PMID 19669251
Response rate37.5% (6 of 16) responded.Human RCTn = 16Internal medicine 2003, PMID 14606705
Low vs high doseThe low and high dose groups did not differ significantly.Human RCTn = 16Internal medicine 2003, PMID 14606705
Absorption and accumulationAbsorption was good with a Tmax of 1-2 hours across formulations.Human RCTn = 9International journal of clinical pharmacology and therapeutics 1999, PMID 10027483
Elimination half-lifeNo accumulation; elimination half-life under 3 hours.Human RCTn = 9International journal of clinical pharmacology and therapeutics 1999, PMID 10027483
Complete response at end of treatmentComplete response was 5 of 17 (29.4%) with T-alpha1 and 7 of 16 (43.8%) with interferon alfa, not significantly different.Human RCTn = 33Hepatology 1996, PMID 8855175
ALT normalisationOne thymosin alpha 1 patient and no placebo patient normalised ALT by the end of treatment.Human RCTn = 19Liver 1996, PMID 8873009
Non-recovery rateAfter adjustment, thymosin alpha 1 use was associated with a higher non-recovery rate (OR 1.5); sicker patients were more likely to be treated.Human observationaln = 2282Frontiers in immunology 2021, PMID 34408744
CD4+ T cell recoveryCD4+ and CD8+ T cell increases did not differ between treated and untreated groups (p=0.851 and p=0.842).Human observationaln = 275Frontiers in immunology 2021, PMID 34149679
28-day mortality in critical typeIn the critical-type subgroup, thymosin alpha 1 was associated with lower 28-day mortality (HR 0.11, P=0.013).Human observationaln = 334International immunopharmacology 2020, PMID 32795897
HCV-RNA clearance and normal ALT at week 48Complete HCV-RNA clearance and normal ALT at week 48 in 45.5% of patients (combination with interferon).Human uncontrolled trialn = 12Journal of the Medical Association of Thailand = Chotmaihet thangphaet 2001, PMID 11529376
All-cause mortalityPooled all-cause mortality was lower (RR 0.53) but certainty is very low.Meta-analysisn = 1349The Cochrane database of systematic reviews 2026, PMID 42713852
Histological improvement and quality of lifeLittle to no effect on quality of life or histology, with very low certainty.Meta-analysisn = 1349The Cochrane database of systematic reviews 2026, PMID 42713852
28-day mortality (all RCTs)Pooling all included RCTs, thymosin alpha 1 reduced 28-day mortality (OR 0.73, P = 0.003).Meta-analysisn = 1927Frontiers in cellular and infection microbiology 2025, PMID 40969554
High-quality and multicentre trialsHigh-quality (OR 0.82) and multicentre (OR 0.86) subgroups showed no significant mortality benefit.Meta-analysisn = 1927Frontiers in cellular and infection microbiology 2025, PMID 40969554
COVID-19 mortalityMortality was lower (RR 0.59, p = 0.02) but ventilation need and hospital stay did not differ; heterogeneity was high.Meta-analysisInflammopharmacology 2023, PMID 37845598
COVID-19 mortalityOverall mortality did not differ (RR 1.03, p = 0.92); the authors do not support use in hospitalized adults.Meta-analysisn = 5352International immunopharmacology 2023, PMID 36527881

Showing the first 20 of 23 rows, strongest sources first.

Not shown in any study we cite. Searches behind this page: PubMed search on 2 Oct 2026 for “("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab])”: 956 results. PubMed search on 2 Oct 2026 for “("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND (randomized[tiab] OR "clinical trial"[pt] OR "meta-analysis"[pt])”: 136 results. PubMed search on 2 Oct 2026 for “("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab])”: 17 results. PubMed search on 2 Oct 2026 for “("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND (sepsis[tiab] OR septic[tiab])”: 51 results.

Claim: it boosts the immune system

A retrospective COVID-19 study found thymosin alpha 1 may have no benefit on restoring CD4+ and CD8+ T cell counts or on virus clearance.[9]

A sepsis review pooled 8 studies with 721 patients and found HLA-DR levels increased with thymosin alpha 1, one of the immune markers it measured.[27]

That review rated the evidence behind its conclusions as low, given small samples and weak reporting.[27]

Claim: it improves survival in sepsis

In the TESTS trial, 127 people (23.4%) on thymosin alpha 1 and 132 (24.1%) on placebo died within 28 days, a hazard ratio of 0.99.[1]

The TESTS authors found no clear evidence that it decreases 28 day all cause mortality in adults with sepsis.[1]

A pooled analysis of sepsis trials reported an odds ratio of 0.73 for 28-day mortality overall, but 0.82 in the high-quality trials and 0.86 in the multicentre ones, neither showing a benefit.[13]

Claim: it helps COVID-19

One pooled analysis of 8 studies found lower mortality with thymosin alpha-1 in moderate to critical COVID-19 (risk ratio 0.59), though it asks for randomised trials to verify it.[14]

Another pooled analysis found no statistically significant effect on mortality (risk ratio 1.03).[15]

A multicentre cohort study linked thymosin alpha 1 to a higher non-recovery rate after adjustment (odds ratio 1.5).[8]

Claim: it helps hepatitis and the liver

A Cochrane review in chronic hepatitis B said thymosin-alpha-1 may reduce all-cause mortality (risk ratio 0.53, 3 studies, 907 participants) on very low-certainty evidence.[12]

The same review concluded that the authors are not sure whether it reduces mortality or serious adverse events.[12]

Claim: bodybuilding and recovery

None of the 9 abstracts cached for this page studied athletes or measured muscle: they cover sepsis, COVID-19, chronic hepatitis B, and trial syntheses of those conditions.

Calculated from abstracts checked 39814420, 40969554, 27633969, 37845598, 36527881, 34408744, 32795897, 34149679, 42713852; athlete studies found 0. Formula: count of cached abstracts naming athletes or muscle outcomes

How much immune-system research exists

A PubMed search of thymosin alpha 1 with immune-system terms (2026-10-02) found 222 human-only papers and 101 under the animal filter; 42 carried a randomized-trial tag.

Calculated from pubmed query ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND (immune[tiab] OR immunity[tiab] OR immunomodulat*[tiab] OR immunodefic*[tiab] OR immunostimul*[tiab]); date 2026-10-02; human only count 222; animal filter count 101; randomized filter count 42. Formula: counts as recorded in the goals.json ledger (PubMed [tiab] query with the human-only, animal and RCT filters shown)

Common questions

Is Thymosin Alpha-1 proven to work?

The strongest study we summarise for Thymosin Alpha-1 is human rct evidence, among 18 studies. A trial result is not an approval; see the legal status.

What does thymosin alpha 1 do?

Thymalfasin is described as a 28-amino acid synthetic polypeptide, originally isolated from a bovine thymus extract.[28]

What is thymosin alpha 1 peptide used for in trials?

In the cached trials it was used as an immunomodulator, for example added to chemoembolization in unresectable hepatocellular carcinoma.[3]

More on Thymosin Alpha-1

Sources

  1. 1The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial.BMJ (Clinical research ed.) · 2025PMID 39814420Accessed 2 Oct 2026
  2. 2Thymosin alpha 1 is associated with improved cellular immunity and reduced infection rate in severe acute pancreatitis patients in a double-blind randomized control study.Inflammation · 2011PMID 20549321Accessed 2 Oct 2026
  3. 3A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma.Hepatology international · 2009PMID 19669251Accessed 2 Oct 2026
  4. 4A pilot study of thymosin alpha1 therapy for chronic hepatitis B patients.Internal medicine (Tokyo, Japan) · 2003PMID 14606705Accessed 2 Oct 2026
  5. 5Pharmacokinetics of thymosin alpha1 after subcutaneous injection of three different formulations in healthy volunteers.International journal of clinical pharmacology and therapeutics · 1999PMID 10027483Accessed 2 Oct 2026
  6. 6A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody--and hepatitis B virus DNA--positive chronic hepatitis B.Hepatology (Baltimore, Md.) · 1996PMID 8855175Accessed 11 Oct 2026
  7. 7A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C.Liver · 1996PMID 8873009Accessed 11 Oct 2026
  8. 8Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort Study.Frontiers in immunology · 2021PMID 34408744Accessed 2 Oct 2026
  9. 9Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients.Frontiers in immunology · 2021PMID 34149679Accessed 2 Oct 2026
  10. 10Thymosin α1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study.International immunopharmacology · 2020PMID 32795897Accessed 2 Oct 2026
  11. 11The combined treatment of interferon alpha-2a and thymosin alpha 1 for chronic hepatitis C: the 48 weeks end of treatment results.Journal of the Medical Association of Thailand = Chotmaihet thangphaet · 2001PMID 11529376Accessed 11 Oct 2026
  12. 12Thymosin-ɑ1 for people with chronic hepatitis B.The Cochrane database of systematic reviews · 2026PMID 42713852Accessed 2 Oct 2026
  13. 13Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials.Frontiers in cellular and infection microbiology · 2025PMID 40969554Accessed 2 Oct 2026
  14. 14The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression.Inflammopharmacology · 2023PMID 37845598Accessed 2 Oct 2026
  15. 15Thymosin alpha1 use in adult COVID-19 patients: A systematic review and meta-analysis on clinical outcomes.International immunopharmacology · 2023PMID 36527881Accessed 2 Oct 2026
  16. 16PubMed search: ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) (956 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  17. 17PubMed search: ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND (randomized[tiab] OR "clinical trial"[pt] OR "meta-analysis"[pt]) (136 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  18. 18PubMed search: ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (17 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  19. 19PubMed search: ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND (sepsis[tiab] OR septic[tiab]) (51 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  20. 20PubMed search: ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND (COVID-19[tiab] OR SARS-CoV-2[tiab]) (44 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  21. 21PubMed search: ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND (hepatitis[tiab]) (131 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  22. 22PubMed search: ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND ("meta-analysis"[pt] OR "systematic review"[pt]) (25 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  23. 23PubMed search: ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND (allerg*[tiab] OR asthma[tiab] OR rhinitis[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  24. 24PubMed search: ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (143 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  25. 25PubMed search: ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND (randomized[tiab] OR "clinical trial"[pt] OR "phase II"[tiab] OR "phase I"[tiab]) AND ("adverse events"[tiab] OR "adverse effects"[tiab] OR toxicity[tiab] OR "injection site"[tiab] OR tolerated[tiab]) (37 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  26. 26PubMed search: ("thymosin alpha 1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab]) AND ("injection site"[tiab] OR "local discomfort"[tiab] OR "side effects"[tiab]) (16 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  27. 27The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials.BMC infectious diseases · 2016PMID 27633969Accessed 2 Oct 2026
  28. 28Thymalfasin for the treatment of chronic hepatitis B.Expert review of anti-infective therapy · 2004PMID 15482167Accessed 2 Oct 2026

Found an error? Report a correction.